HANHAI Silicon Valley
瀚海硅谷中心

**Alex Zhang, PhD, MBA**
*CEO*

**Alex Zhang,** is the CEO of Hanhai Silicon Valley., an early stage investor and cross-border accelerator for startups in San Francisco Bay Area. Prior to Hanhai, Alex was the Managing Partner of Enverest, LLC., a Silicon Valley-based innovation solutions and investment advisory firm with branch offices in China and Singapore. Prior to co-founding Enverest, Dr. Zhang spent nearly five years at Thermo Fisher Scientific, where he was responsible for 4 business development deals exceeding $10 M, and played a key role in several billion-dollar acquisitions in MedTech. From 2001 to 2009, Dr. Zhang was a Senior Scientist at Tularik Inc. (acquired by Amgen in 2004), where he led drug discovery endeavors in oncology, cardiovascular and metabolic diseases therapeutic areas.

Dr. Zhang received MBA degree at Cornell University, PhD in Organic and Analytical Chemistry at Texas A&M University, and BS in Chemistry at Shandong University. During his graduate research, he focused on the design and synthesis of therapeutic peptoids, as well as biological mass spectrometry. His research has led to publication of more than 20 peer reviewed articles and 4 patents.

Dr. Zhang has served multiple leadership roles in the Executive Council of CABS, including as the President in 2017-18. Over the past decade, Dr. Zhang has advised a number of successful MedTech and digital health startups based in Silicon Valley.

ChemPartner
Dedicated to LifeScience

**Jun Xiang, PhD**
*General Manager*
*ChemPartner Biologics (Shanghai) Co., Ltd.*

**Jun Xiang,** has near 20 years' experience in R&D of biological drug products, and is the General Manager of ChemPartner Biologics (Shanghai) Co., Ltd. which provides one-stop CDMO services for biologics, covering from development of cell line, cell culture and purification process, and formulation to pilot-scale and commercial scale manufacturing. Prior to joining CPB, Dr. Xiang was a Sr. VP of Biotechnology Institute of Shanghai CP Guojian (Now name changed to Sunshine Guojian Pharmaceutical (Shanghai) Co. Ltd.). He was responsible for research and development of novel formulations and drug delivery systems as well as late stage production processes for antibody drug products. He was also in charge of the entire development of antibody-drug conjugates (ADC)， and has established ADC technology platform in CP Guojian along with completion of one ADC drug product IND filing. Dr. Xiang previously worked as a Staff Scientist at Bayer HealthCare Pharmaceuticals in US. He has tremendous experience in late stage development of biological drug products, especially in the various CMC fields. He served as the President of Chinese American Biopharmaceutical Society (CABS) from 2005 to 2006, and was a Board member of CABS from 2004 to 2018. He was also the Chief Managing Editor of the journal Trends in Bio/pharmaceutical Industrial from 2008 to 2011.

# iDNA

**Huijun Zhou, Ph.D., FACMG**
*Founder & CEO*

**Huijun Zhou** Dr. Huijun Zhou  is CEO and co-founder of Doctor Chain and iDNA.com.cn. Dr. Zhou received her Ph.D. in molecular biology and genetics from Cornell University and completed her post-doctoral medical genetics training at the Stanford University School of Medicine. She is a clinical molecular geneticist, board-certified by the American Board of Medical Genetics. She is the Program Chair of Chinese American BioPharmaceutical Society (CABS) Entrepreneurship Club.

MORRISON
FOERSTER

**Joseph Benkert**
*Senior Advisor*
*National Security Group*

**Joseph Benkert** is a senior advisor in Morrison & Foerster's National Security practice group. He advises clients on critical national security matters pertaining to the Committee on Foreign Investment in the United States (CFIUS), export controls, and various regulatory and compliance issues. Mr. Benkert previously served as a leading civilian official in the Department of Defense (DoD) under both the Bush and Obama administrations, including as Assistant Secretary of Defense for Global Security Affairs after being nominated by President Bush and confirmed by the Senate. While at the DoD, Mr. Benkert led the department's involvement in numerous complex matters before CFIUS. Mr. Benkert's responsibilities also included managing technology security policy, the reform of export control processes, numerous sensitive nonproliferation projects, and a broad range of other defense-related issues. More recently, Mr. Benkert served as a Vice President of a leading global consultancy group, under former Secretary of Defense William Cohen. Mr. Benkert was a career Navy officer with extensive experience both in operational command and in national security policy formulation and implementation.

FINNEGAN
美国飞翰律师事务所

**Michael Liu Su, MS, JD**
*Attorney*
*Intellectual Property Law*

**Michael Liu Su** is an attorney at intellectual property law firm Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. Based in Finnegan's Palo Alto office, Mike's practice spans both patent and trade secret matters, involving industries such as biotechnology, pharmaceuticals, chemical, medical devices, and computer technology. His litigation experience includes representing clients before state and federal trial and appellate courts, and before arbitrators. He has also successfully litigated before the Patent Trial and Appeal Board (PTAB) in post-grant proceedings that involve patent validity. He also maintains an active patent procurement and due diligence practice. In his graduate work, Mike focused on cancer research at the cellular level, specifically in the areas of cell cycles, cell migration, and cancer metastasis. Mike earned an M.S. in genome sciences from National Yang-Ming University in Taiwan and a J.D. from U.C. Berkeley, School of Law.

Deloitte.

**Vivien Wang, MS**
*Partner*
*International Tax*

**Vivien Wang** has over 20 years of public accounting and international tax experiences, providing tax consulting, compliance and tax accounting assurance services to various high-tech, biotech and venture capital clients. Her experience includes structuring and globally managing both U.S. inbound and outbound investments. Vivien specializing in the IPO restructuring, merger and acquisition integration and implementation of worldwide IP migrations and supply chain strategies for multinational clients.

Vivien is our US Inbound Practice leader for the West Region, focusing on serving foreign company's investments in the US through both M&A and greenfield investment. Vivien is also the National Tax Leader of Deloitte's US Chinese Services Group, specializing in China strategy planning for US companies and investment funds and US inbound investment planning for China based investors. In this role, Vivien serves many leading Asia based private equity and venture capital firms, and technology companies and their investments in the U.S. Vivien obtained her MS in Taxation at San Jose State University, BS in Accounting from University of Utah and BA in International Finance, Shenzhen University.

**Mike (Yiding) Chen**
*Founder and CEO*

**Mike (Yiding) Chen** previoiusly worked as application scientist and project manager at Life Technologies and Thermofisher. Mike Chen founded ACROBiosystems in 2010, a biotech company that is committed to providing high quality protein reagent products with unique protein labeling technologies, specially designed for antibody drug development. The company keeps focusing on timely addressing needs of customers from over 60 countries. Mike Chen has over 15 years experience in pharmaceutical and biotech industry, developed the first serum-free cell culture process for rabies vaccine production in China. He has led the company to market their products to over 60 countries

**Connie Sun, PhD**
*SVP, Business & Corporate Development*

**Connie Sun** is Senior Vice President of Business & Corporate Development at Pharmaron. She is responsible for cross-functional business and corporate development, partnership alliance management and program management. Prior to joining Pharmaron, she has 16 years of drug discovery and development experience at biotech and pharma companies. She is author of 35 publications and inventor of 47 patents and is an inventor of Sutent®, which is currently marketed by Pfizer. She previously held positions as Head of Chemistry at Poniard Pharmaceuticals, Senior Director at AGY Therapeutics Inc. and Director of Chemistry at Pfizer (SUGEN).
Connie holds a Ph.D. in Medicinal Chemistry from University of North Carolina, Chapel Hill, North Carolina. Her postdoc training was at Parke-Davis, Warner-Lambert (later Pfizer), Ann Arbor, MI.

JOINN Biologics

**Tao He, PhD**
*Co-Founder and SVP*

**Tao He** is the co-founder of JOINN Biologics US Inc., a premier CDMO dedicated to biologics development and manufacturing. He has over 20+ years' experience in pharma/biotech (Novartis, Celera Genomics, Wyeth, and Pfizer) and is an expert in protein-based drug discovery and development. He commands in-depth knowledge and experience with managing biologics development programs and is widely recognized as an industry leader and senior subject matter expert in the field of protein analytics. Tao was a pioneer in establishing developability assessment for biologics development and was a key note speaker at Bioprocessing Summit. As a project lead, he led and supported multiple biologics programs from preclinical through IND filing. Tao received his Ph.D. from University of Maryland and coauthored over 25 peer reviewed publications and nine granted patents

Henlius

**Scott Liu, PhD**

*Co-founder, President and CEO*

**Scott Liu** is the Co-founder, President and CEO at Shanghai Henlius Biotech Inc., a global biopharmaceutical company focusing on the development, production and commercialization of high-quality and affordable biosimilar, biobetter and novel therapeutic monoclonal antibodies. Under his leadership, Henlius has become a leader of therapeutic monoclonal antibodies to treat a range of chronic and life-threatening diseases in China. Dr. Liu has more than 25 years of experience in biopharmaceutical R&D, manufacturing and quality management. Prior to joining Fosun Group in 2010, he has previously served several executive positions such as Vice President of R&D at United Biomedical, the Founding Director of the Biologics QC Department at Bristol-Myers Squibb (Syracuse, USA), and the Director of QAL (QC) at Amgen (Fremont, USA). Because of his extensive knowledge in quality and control of biologics, Dr. Liu had provided assistance to the CDE of CFDA in developing and implementing quality standards for biosimilars and novel biologics in China. Furthermore, Dr. Liu led the promotion of industry-wide adoption of single-use manufacturing technology to support the production of clinical and commercial monoclonal antibody therapeutics, and actively participated in the development of《Technical Guidelines of Biosimilar Development and Evaluation》to promote the innovation and globalization of the biopharmaceutical industry in China. Dr. Liu was the recipient of the the Bristol-Myers Squibb“Technical Operations Presidential Award”in 2004 and was recognized in 2013 as an expert of the "Thousand Talents Plan of Shanghai”. Dr. Liu received his Ph.D. degree in Biology from the Purdue University with postdoctoral training in Biology at Stanford University and studied business administration (iMBA courses) at the Syracuse University.

**Jingrong Jean Cui, PhD**
*Scientific Founder and CSO*

**Jingrong Jean Cui,** is the Scientific Founder, Director, and Chief Scientific Officer at Turning Point Therapeutics (TP). Dr. Cui is an internationally renowned oncology drug designer with more than 20 years of experience in drug discovery and project management at major pharmaceutical and biotech companies. At TP, Dr. Cui has been focusing on addressing drug resistance issue in precision medicine, an urgent unmet medical need in oncology. Currently, TP's lead clinical compound TPX-0005 (Repotrectinib) is in Phase 1/2 clinical trial and two other pipeline projects are expected to enter clinical development in 2019. Prior to TP, Dr. Cui was Associate Fellow at Pfizer and she is the lead inventor for Pfizer's oncology drugs Xalkori™ (crizotinib) and Lorbrena™ (lorlatinib). Dr. Cui also designed Pfizer's clinical compound PF-04217903 for c-MET program and participated in development of oncology drug SUTENT.

Dr. Cui is the author of more than 60 scientific publications and patents. Among them, the patent for Crizotinib (US patent 7858643) won the 38th National Inventor of the Year Award in 2011. This highly prestigious award is selected by Intellectual Property Owners Association to recognize a high impact invention in U.S. Each year, only one patent across all industries is selected for this special award. Dr. Cui was a winner of the 2013 American Chemical Society's Heroes of Chemistry Award. She was the winner of the inaugural CABS K. Fong Award in Life Sciences in 2013. For her significant accomplishments at Pfizer, Dr. Cui received Pfizer's Worldwide Research and Development Achievement Awards in 2006 and 2012, and Innovation Award in 2011.

Dr. Cui obtained her Ph.D. in Organic Chemistry from The Ohio State University and her postdoctoral training at University of California, Berkeley. Dr. Cui received her B.S. and M.S. from the University of Science and Technology of China.

Apexigen

**Mark Nevins, MS, MBA**
*VP, Business Development*

**Mark Nevins** currently serves as Vice President, Business Development of Apexigen. Prior to joining Apexigen, Mr. Nevins served as Director, Business Development at Aradigm Corp., and at Abgenix, Inc. and held positions of increasing business development responsibility at G. D. Searle & Co, the pharmaceutical subsidiary of Monsanto Company.

Mr. Nevins has more than 35 years of pharmaceutical industry experience; nearly 20 of those years have been devoted to business development and licensing. He has negotiated license agreements and strategic alliances, managed research collaborations, and, while at Abgenix, he participated in the transformative strategic alliance with AstraZeneca for the development of antibodies against multiple oncology targets. Earlier in his career, he conducted drug discovery research for G. D. Searle & Co. Mr. Nevins holds a Master's Degree in Psychology from Central Michigan Universty and an MBA from Dominican University.

MERCK

**Yanyan Zheng, PhD**
*Principle Scientist*

**Yanyan Zheng** is currently a Principal Scientist in Discovery Oncology at Merck & Co. Inc., leading the tumor intrinsic targeting and translational pathology group. As a seasoned drug hunter, she is interested in bringing innovative therapeutics to patients with unmet medical need. Her expertise encompasses a broad range of processes in drug development, from target identification/validation, biologics discovery, to translational research. Dr. Zheng received her Ph.D. in Molecular Microbiology and Immunology, with a concurrent M.S. degree in Biostatistics, from University of Southern California. She conducted her Postdoctoral Fellowship training in Cancer Biology at Stanford University..